Rilonacept - Kiniksa Pharmaceuticals/Regeneron Pharmaceuticals
Alternative Names: ARCALYST; Arcalyst; IL-1-Cytokine-Trap; IL-1-Trap; Interleukin-1 Trap; KPL 914; RGN-303Latest Information Update: 04 Jan 2024
At a glance
- Originator Regeneron Pharmaceuticals
- Developer Boston University; Charite - Universitatsmedizin Berlin; Kiniksa Pharmaceuticals; Regeneron Pharmaceuticals
- Class Anti-inflammatories; Antianaemics; Antirheumatics; Cardiovascular therapies; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Interleukin 1 alpha inhibitors; Interleukin 1 beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cryopyrin-associated periodic syndromes; Inborn genetic disorders; Pericarditis
- Phase II Urticaria
- Phase I/II Systemic scleroderma
- Discontinued Anaemia; Gout; Juvenile rheumatoid arthritis; Osteoarthritis; Polymyalgia rheumatica; Rheumatoid arthritis
Most Recent Events
- 04 Jan 2024 Launched for Pericarditis (Recurrent) in Israel (SC) before January 2024
- 04 Jan 2024 No development reported - Phase-III for Pericarditis (Recurrent) in Australia (SC)
- 04 Jan 2024 No development reported - Phase-III for Pericarditis (Recurrent) in Italy (SC)